Gene therapy for haemophilia...yes, but...with non-viral vectors?

Haemophilia

Volumn 15, Issue 3, 2009, Pages 811-816

  Liras, Antonio ^a   Olmedillas, S ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b 'Victoria Eugenia'of Haemophilia   (Spain)

Author keywords

Gene therapy; Haemophilia; Non viral vectors; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; LIPOSOME; PARVOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RETROVIRUS VECTOR;

ARTICLE; CELL THERAPY; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PATIENT SAFETY; PHENOTYPE; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA A; HUMANS;

EID: 65449140491     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02010.x     Document Type: Article

References (48)

1. Mannucci PM, Tuddenham EG. The hemophilias: From royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
3. Key NS, Negrier C. Coagulation factor concentrates: Past, present, and future. Lancet 2007; 370: 439-48.
4. Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T.J. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. Thromb Haemost 2007; 5: 901-6.
5. Liras A. Recombinant proteins in therapeutics: Haemophilia treatment as an example.HInt Arch Med 2008; 1: 4. Available at: http:// www.intarchmed.com/content/1/1/4 (last accessed on 23 January 2009).
6. Pipe SW. Recombinant clotting factors. Thromb Haemost 2008; 99: 840-50.
7. Mersich C, Billes W, Pabinger I, Jungbauer A. Peptides derived from a secretory yeast library restore factor VIII activity in the presence of an inhibitory antibody. Biotechnol Bioeng 2007; 98: 12-21.
8. Ramani K, Miclea RD, Purohit VS et al. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci 2008; 97: 1386-98.
9. Ramani K, Purohit V, Miclea R et al. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. J Pharm Sci 2008; 97: 3753-64.
10. Powell JS. Liposomal approach towards the development of a longer-acting factor VIII. Haemophilia 2007; 13 (Suppl. 2): 23-8.
11. Powell JS, Nugent DJ, Harrison JA et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008; 6: 277-83.
12. Martinowitz U, Lalezari S, Luboshitz J et al. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A. Haemophilia 2008; 14: 1122-4.
13. Spira J, Plyushch OP, Andreeva TA, Khametova RN. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008; 100: 429-34.
14. Lillicrap D, Vandendriessche T, High K. Cellular and genetic therapies for haemophilia. Haemophilia 2006; 12 (Suppl. 3): 36-41.
15. Liras A. Mission of World Federation of Haemophilia, Biotechnology and treatment for all? The paradox. Haemophilia 2008; 14: 920-2.
16. Fair JH, Cairns BA, Lapaglia MA et al. Correction of factor IX deficiency in mice by embryonic stem cells differentiated in vitro. Proc Natl Acad Sci USAH2005; 102: 2958-63. Available at: http:// www.pubmedcentral.nih.gov/picrender.fcgi?artid=548326&blobtype=pdf (last accessed on 23 January 2009).
17. Follenzi A, Benten D, Novikoff P et al. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin IHvest 2008 ; 118: 935-45. Available at: http:// www.jci.org/articles/view/32748 (last accessed on 23 January 2009).
18. Liras A. Gene therapy for haemophilia: The end of a "royal pathology"in the third millennium? Haemophilia 2001; 7: 441-5.
19. Giangrande PL. Gene therapy for hemophilia? No. J Thromb Haemost 2004; 2: 1236-7. AvailHble at: http://www3.interscience.wiley.com/cgi-bin/ fulltext/118817905/PDFSTART (last accessed on 23 January 2009).
20. Negrier C. Gene therapy for hemophilia? Yes. J Thromb Haemost 2004; 2: 1234-5. Available at: http://www3.interscience.wiley.com/cgi-bin/ fulltext/118817912/PDFSTART (last accessed on 23 January 2009).
21. Liras A. Gene Therapy memory or hope? 1st ed. Madrid: Complutense Ed, 2008. e-book, 236 p. Available at: http:// www.editorialcomplutense.com/detalle_libro.php?id=78 (last accessed on 23 January 2009).
22. Mannucci PM. Back to the future: A recent history of haemophilia treatment. Haemophilia 2008; 14 (Suppl. 3): 10-8.
23. Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol 2008; 140: 479-87. AvaHlable at: http://www3.interscience.wiley.com/cgi-bin/ fulltext/119388684/PDFSTART (last accessed on 23 January 2009).
24. Xu L, Nichols TC, Sarkar R et al. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci USA 2005; 102: 6080-5. Available at: http://www.pubmedcentral.nih.gov/ picrender.fcgi?artid=1087916&blobtype=pdf (last accessed on 23 January 2009).
25. Ide LM, Gangadharan B, Chiang KY et al. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and non-myeloablative conditioning regimens. Blood 2007; 110: 2855-63. Available at: http://bloodjournal.hematologylibrary.org/cgi/reprint/110/ 8/2855 (last accessed on 23 January 2009).
26. Bigger BW, Siapati EK, Mistry A et al. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther 2006; 13: 117-26.
27. Sarkar R, Mucci M, Addya S et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther 2006; 17: 427-39.
28. Jiang H, Lillicrap D, Patarroyo-White S et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A micH and dogs. Blood 2006; 108: 107-15. Available at: http://bloodjournal.hematologylibrary.org/cgi/reprint/108/1/107 (last accessed on 23 January 2009).
29. Hasbrouck NC, High KA. AAV-mediated gene transfer for the treatment of hemophilia B: Problems and prospects. Gene Ther 2008; 15: 870-5.
30. Nathwani AC, Gray JT, McIntosh J et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in non-human primateH. Blood 2007; 109: 1414-21. Available at: http:// bloodjournal.hematologylibrary.org/cgi/content/full/109/4/1414 (last accessed on 23 January 2009).
31. Graham T, McIntosh J, Work LM et al. Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats. Genet Vaccines Ther 2008; 6: 9. Available at: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid= 2267784&blobtype=pdf. (last accessed on 23 January 2009).
32. Miao CH. A novel gene expression system: Non-viral gene transfer for hemophilia as model systems. Adv Genet 2005; 54: 143-77.
33. Avigen, Inc. A Phase I Safety Study in Subjects With Severe Hemophilia B (factor IX Deficiency) Using Adeno-Associated Viral Vector to Deliver the Gene for Human factor IX Into the Liver. Available at: http:// clinicaltrials.gov/ct2/show/NCT00076557?term=gene+transfer+and+ haemophilia&rank=1 (last accessed on 23 January 2009).
34. Manno CS, Pierce GF, Arruda VR et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-7.
35. Schuettrumpf J, Liu JH, Couto LB et al. Inadvertent germline transmission of aav2 vector: Findings in a rabbit model correlate with those in a human clinical trial. Mol Ther 2006; 13: 1064-73.
36. Manno CS. A Phase 1 Safety Study in Subjects With Severe Hemophilia B (factor IX Deficiency) Using Adeno-Associated Viral Vector to Deliver the Gene for Human factor IX Into the Liver Coupled With Transient Immunomodulation. Available at: http://clinicaltrials.gov/ct2/show/ NCT00515710?term=gene+transfer+and+haemophilia&rank=2 (last accessed on 23 January 2009).
37. Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111: 4431-4H. Available at: http://bloodjournal. hematologylibrary.org/cgi/content/full/111/9/4431 (last accessed on 23 January 2009).
38. Fehse B, Roeder I. Insertional mutagenesis and clonal dominance: biological and statistical considerations. Gene Ther 2008; 15: 143-53.
39. Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol 2007; 14: 337-42.
40. Romano G. The controversial role of adenoviral-derived vectors in gene therapy programs: Where do we stand? Drug News Perspect 2006; 19: 99-106.
41. Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther 2005; 5: 323-31.
42. High K. Gene transfer for hemophilia: Can therapeutic efficacy in large animals be safely translated to patients? J Thromb Haemost 2005; 3: 1682-91.
43. Gabrovsky V, Calos MP. Factoring nonviral gene therapy into a cure for hemophilia A. Curr Opin Mol Ther 2008; 10: 464-70.
44. Roth DA, Tawa NE Jr, O'Brien JM et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; H44: 1735-42. Available at: http://content.nejm.org/cgi/ reprint/344/23/1735.pdf (last accessed on 23 January 2009).
45. Liras A. ConfiHe Grant by Baxter BioScience Spain. J Spanish Federation of Haemophilia 2008; 46: 48.
46. Picinich SC, Mishra PJ, Mishra PJ et al. The therapeutic potential of mesenchymal stem cells. Cell- and tissue-based therapy. Expert Opin Biol Ther 2007; 7: 965-73.
47. Kimmelman J. Staunch protections: The ethics of haemophilia gene transfer research. Haemophilia 2008; 14: 5-14.
48. Hauck B, Murphy SL, Smith PH et al. Undetectable Transcription of cap in a clinical AAV vector: Implications for preformed capsid in immune responses. Mol Ther 2009; 17: 144-52.